(NASDAQ: ACHV) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 41.6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 8.82%.
Achieve Life Sciences's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast ACHV's revenue for 2023 to be $1,054,305,286, with the lowest ACHV revenue forecast at $1,054,305,286, and the highest ACHV revenue forecast at $1,054,305,286. On average, 1 Wall Street analysts forecast ACHV's revenue for 2024 to be $1,685,454,028, with the lowest ACHV revenue forecast at $1,685,454,028, and the highest ACHV revenue forecast at $1,685,454,028.
In 2025, ACHV is forecast to generate $2,209,020,598 in revenue, with the lowest revenue forecast at $2,209,020,598 and the highest revenue forecast at $2,209,020,598.